Rational design of antitumor prostaglandins with high biological stability

Journal of Medicinal Chemistry

Volumn 41, Issue 16, 1998, Pages 3084-3090

  Suzuki, Masaaki ^a   Kiho, Toshihiro ^b   Tomokiyo, Keiichiro ^a   Furuta, Kyoji ^a   Fukushima, Shoji ^c   Takeuchi, Yoshikazu ^c   Nakanishi, Makoto ^d   Noyori, Ryoji ^b  

^a GIFU UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c KOBE GAKUIN UNIVERSITY   (Japan)

^d NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 9 OXOPROSTA 7,10,13 TRIENOIC ACID; 15 HYDROXY 9 OXOPROSTA 7,10,13 TRIENOIC ACID METHYL ESTER; ANTINEOPLASTIC AGENT; PROSTAGLANDIN A1; PROSTAGLANDIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; DRUG STRUCTURE; DRUG SYNTHESIS; GLIOMA CELL; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; G1 PHASE; HUMANS; PROSTAGLANDINS; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0032581643     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9801657     Document Type: Article

References (63)

1. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
2. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
3. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
4. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
5. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
6. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
7. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
8. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
9. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
10. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
11. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells..
12. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
13. 12-Prostaglandin
14. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
15. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
16. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
17. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
18. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
19. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
20. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
21. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
22. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
23. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
24. 2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells.
25. 1 Methyl Esters with Thiols. J. Am. Chem. Soc. 1997, 119, 2376-2385 and references therein.
26. (a) Sugiura, S.; Toru, T.; Tanaka, T.; Hazato, A.; Okamura, N.; Bannai, K.; Manabe, K.; Kurozumi, S.; Noyori, R. Synthesis of New Antineoplastic Prostaglandins. Chem. Pharm. Bull. 1984, 32, 4658-4661.
27. (b) Suzuki, M.; Kawagishi, T.; Yanagisawa, A.; Suzuki, T.; Okamura, N.; Noyori, R. Three-Component Coupling Synthesis of Prostaglandins: The Aldol Route. Bull. Chem. Soc. Jpn. 1988, 61, 1299-1312.
28. Suzuki, M.; Morita, Y.; Koyano, H.; Koga, M.; Noyori, R. Three-Component Coupling Synthesis of Prostaglandins. A Simplified, General Procedure. Tetrahedron 1990, 46, 4809-4822.
29. Noyori, R.; Suzuki, M. An Organometallic Way to Prostaglandins: The Three-Component Coupling Synthesis. Chemtracts: Org. Chem. 1990, 3, 173-197.
30. 2 in Vitro and in Vivo. Cancer Res. 1986, 46, 3538-3542.
31. (a) Noyori, R.; Suzuki, M. Organic Synthesis of Prostaglandins: Advancing Biology. Science 1993, 259, 44-45.
32. (b) Noyori, R.; Koyano, H.; Mori, M.; Hirata, R.; Shiga, Y.; Kokura, T.; Suzuki, M. Unnatural Prostaglandins of Biochemical and Physiological Significance. Pure Appl. Chem. 1994, 66, 1999-2005.
33. Akimaru, K.; Kuo, M. T.; Furuta, K.; Suzuki, M.; Noyori, R.; Ishikawa, T. Induction of MRP/GS-X Pump and Cellular Resistance to Anticancer Prostaglandins. Cytotechnology 1996, 19, 221-227.
34. Akimaru, K.; Nakanishi, M.; Suzuki, M.; Furuta, K.; Noyori, R.; Ishikawa, T. Cell Growth Inhibition by Anticancer Prostaglandin and Its Modulation by MRP/GS-X Pump. Adv. Exp. Med. Biol. 1997, 407, 387-391.
35. 2 and Related Compounds: Preclinical Results and Gene Mechanisms. In Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury; Nigam, S., Marnett, L. J., Honn, K. V., Walden, T. L., Jr., Eds.; Kluwer Academic Publishers: Boston, MA, 1993; pp 737-739.
36. (b) Kikuchi, Y.; Kita, T.; Hirata, J.; Fukushima, M. Preclinical Studies of Antitumor Prostaglandins by Using Human Ovarian Cancer Cells. Cancer Metastasis Rev. 1994, 13, 309-315.
37. 2 and Related Compounds. Mode of Action in G1 Arrest and Preclinical Results. Ann. N. Y. Acad. Sci. 1994, 744, 161-165.
38. 1 in the Sera. Tetrahedron 1997, 53, 17009-17014.
39. Polet, H.; Levine, L. Metabolism of Prostaglandins E, A, and C in Serum. J. Biol. Chem. 1975, 250, 351-357 and references therein. See also: Smith, J. B.; Silver, M. J.; Ingerman, C. M.; Kocsis, J. J. Uptake and Inactivation of A-Type Prostaglandins by Human Red Cells. Prostaglandins 1975, 9, 135-145.
40. Polet, H.; Levine, L. Metabolism of Prostaglandins E, A, and C in Serum. J. Biol. Chem. 1975, 250, 351-357 and references therein. See also: Smith, J. B.; Silver, M. J.; Ingerman, C. M.; Kocsis, J. J. Uptake and Inactivation of A-Type Prostaglandins by Human Red Cells. Prostaglandins 1975, 9, 135-145.
41. For example, see: (a) Ogston, A. G. Interpretation of Experiments on Metabolic Processes, Using Isotopic Tracer Elements. Nature 1948, 162, 963. (b) Casy, A. F. The Steric Factor in Medicinal Chemistry Dissymmetric Probes of Pharmacological Receptors; Plenum Press: New York, 1993. (c) Dugas, H. Bioorganic Chemistry, 3rd ed.; Springer: New York, 1996.
42. For example, see: (a) Ogston, A. G. Interpretation of Experiments on Metabolic Processes, Using Isotopic Tracer Elements. Nature 1948, 162, 963. (b) Casy, A. F. The Steric Factor in Medicinal Chemistry Dissymmetric Probes of Pharmacological Receptors; Plenum Press: New York, 1993. (c) Dugas, H. Bioorganic Chemistry, 3rd ed.; Springer: New York, 1996.
43. For example, see: (a) Ogston, A. G. Interpretation of Experiments on Metabolic Processes, Using Isotopic Tracer Elements. Nature 1948, 162, 963. (b) Casy, A. F. The Steric Factor in Medicinal Chemistry Dissymmetric Probes of Pharmacological Receptors; Plenum Press: New York, 1993. (c) Dugas, H. Bioorganic Chemistry, 3rd ed.; Springer: New York, 1996.
44. 2. Prostaglandins 1974, 5, 275-281.
45. 1, a structurally more simplified derivative of 2, also showed a similar tendency in its biological stability and antiproliferative activity; see ref 4.
46. 1 and Congeners. Prostaglandins 1977, 14, 11-19.
47. (b) Tsai, A.; Wu, K. K. Structure-Activity Relationship between Prostacyclin and Its Platelet Receptor. Eicosanoids 1989, 2, 131-143.
48. Hanasaki, K.; Kishi, M.; Arita, H. Phorbol Ester-Induced Expression of the Common, Low-Affinity Binding Site for Primary Prostanoids in Vascular Smooth Muscle Cells. J. Biol. Chem. 1990, 265, 4871-4875.
49. This approach is reminiscent of the recently proposed biochemical methodology called "mirror-image phage display technique" to avoid the degradation of drugs by enzymes: Schumacher, T. N. M.; Mayr, L. M.; Minor, D. L., Jr.; Milhollen, M. A.; Burgess, M. W.; Kim, P. S. Identification of D-Peptide Ligands Through Mirror-Image Phage Display. Science 1996, 271, 1854-1857.
50. (a) Noyori, R.; Tomino, I.; Tanimoto, Y.; Nishizawa, M. Rational Designing of Efficient Chiral Reducing Agents. Highly Enantioselective Reduction of Aromatic Ketones by Binaphthol-Modified Lithium Aluminum Hydride Reagents. J. Am. Chem. Soc. 1984, 106, 6709-6725.
51. (b) Matsumura, K.; Hashiguchi, S.; Ikariya, T.; Noyori, R. Asymmetric Transfer Hydrogenation of α,β-Acetylenic Ketones. J. Am. Chem. Soc. 1997, 119, 8738-8739. (R)-1-Octyn-3-ol, a useful precursor of the unnatural type ω-side chain, is now commercially available.
52. Kitamura, M.; Kasahara, I.; Manabe, K.; Noyori, R.; Takaya, H. Kinetic Resolution of Racemic Allylic Alcohols by BINAP-Ruthenium(II)-Catalyzed Hydrogenation. J. Org. Chem. 1988, 53, 708-710 and references therein.
53. Suzuki, M.; Noyori, R. Conjugate Addition-Enolate-Trapping Reactions. In Organocopper Reagents; Taylor, R. J. K., Ed.; Oxford University Press: New York, 1994; Chapter 9, pp 185-216.
54. Collins, P. W.; Djuric, S. W. Synthesis of Therapeutically Useful Prostaglandin and Prostacyclin Analogues. Chem. Rev. 1993, 93, 1533-1564.
55. These PG derivatives were synthesized by the three-component coupling synthesis using appropriate chiral cyclopentenone and ω-chain units. See the Experimental Section.
56. Hormonal PGs are known to be easily oxidized at the C(15)-hydroxy group and lose their biological activities; see: Samuelsson, B.; Granström, E.; Green, K.; Hamberg, M.; Hammarström, S. Prostaglandins. Annu. Rev. Biochem. 1975, 44, 669-695.
57. MO calculations were carried out using the Gaussian 94 package at MP2/6-31G*//HF/6-31G* level. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Gill, P. M. W.; Johnson, B. G.; Robb, M. A.; Cheeseman, J. R.; Keith, T.; Petersson, G. A.; Montgomery, J. A.; Raghavachari, K.; Al-Laham, M. A.; Zakrzewski, V. G.; Ortiz, J. V.; Foresman, J. B.; Cioslowski, J.; Stefanov, B. B.; Nanayakkara, A.; Challacombe, M.; Peng, C. Y.; Ayala, P. Y.; Chen, W.; Wong, M. W.; Andres, J. L.; Replogle, E. S.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Binkley, J. S.; Defrees, D. J.; Baker, J.; Stewart, J. P.; Headgordon, M.; Gonzalez, C.; Pople, J. A. Gaussian 94, Revision C.3; Gaussian Inc.: Pittsburgh, PA, 1995.
58. 1 Analogs that Suppress Tumor Cell Growth through Induction of p21 and Reduction of Cyclin E. J. Biol. Chem., in press.
59. This result is consistent with the observation in our preliminary experiments that the preservation of the PG concentration in blood is very important for the exhibition of a sufficient in vivo anticancer effect. The increased biological stability may also avoid the severe side effects possibly caused by the metabolite of the antitumor PG.
60. (a) Harper, J. W.; Adami, G. R.; Wei, N.; Keyomarsi, K; Elledge, S. J. The p21 Cdk-Interacting Protein Cip1 Is a Potent Inhibitor of G1 Cyclin-Dependent Kinases. Cell 1993, 75, 805-816.
61. (b) Xiong, Y.; Hannon, G. J.; Zhang, H.; Casso, D.; Kobayashi, R.; Beach, D. p21 Is a Universal Inhibitor of Cyclin Kinases. Nature 1993, 366, 701-704.
62. Review: (c) Hunter, T.; Pines, J. Cycling and Cancer. II: Cyclin D and CDK Inhibitors Come of Age. Cell 1994, 79, 573-582.
63. Ito, T.; Okamoto, S.; Sato, F. Practical Method for Synthesis of Optically Pure Propargylic Alcohols. Tetrahedron Lett. 1989, 30, 7083-7086. †Gifu University.